Neogenomics (NEO) Operating Expenses (2010 - 2026)

Neogenomics (NEO) has reported Operating Expenses for 17 consecutive years, with $101.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 18.61% year-over-year to $101.6 million; the trailing twelve-month figure through Jun 2026 stood at $405.0 million (down 3.05% YoY), and the FY2025 full-year result was $430.2 million, up 12.55% from the prior year.
• Operating Expenses advanced to $101.6 million in Q2 2026 per NEO's latest filing, from $99.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $124.9 million in Q2 2025 and bottomed at $83.2 million in Q4 2022.
• Historically, Operating Expenses has averaged $95.1 million across 5 years, with a median of $95.0 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses jumped 59.24% in 2022, then retreated 18.61% in 2026.
• Over 5 years, Operating Expenses stood at $83.2 million in 2022, then gained by 3.55% to $86.2 million in 2023, then rose by 11.02% to $95.7 million in 2024, then grew by 1.15% to $96.8 million in 2025, then rose by 5.06% to $101.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $101.6 million, $99.1 million, and $96.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.